Kronos Bio (id:8381 KRON)
0.903 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 7:45:04 PM)
Exchange closed, opens in 13 hours 44 minutes
-1.85 USD (-1.85%)
5.61 USD (5.61%)
-4.65 USD (-4.65%)
18.35 USD (18.35%)
-27.76 USD (-27.76%)
-96.83 USD (-96.83%)
About Kronos Bio
Market Capitalization 52.76M
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
| Headquarters (address) |
1300 South El Camino Real San Mateo 94402 CA United States |
| Phone | (650) 781-5200 |
| Website | https://www.kronosbio.com |
| Employees | 58 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | KRON |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.690 - 1.60 |
| Market Capitalization | 52.76M |
| P/E trailing | -0.463 |
| P/E forward | -0.634 |
| Price/Sale | 6.27 |
| Price/Book | 0.324 |
| Beta | 1.86 |
| EPS | -1.43 |
| EPS United States (ID:6, base:3402) | 24.22 |